Very few things have such an impact on biotech stocks.
FDA decisions are among the biggest factors, but given the FDA’s unpredictable nature, there’s still no such thing as a sure trade.
Yet it really doesn’t matter what the FDA says.
What does matter is being in the know and being in the right place at the right time.
Most of us who use the FDA calendar and Phase III trial dates know one thing: The price of a biotech and pharmaceutical company will go up as the date in questions draws closer.
And if you want to maximize your potential return, have any pending dates in hand well in advance.
We’ve been trading FDA decisions in Options Trading Pit, for example, for years… with great success.
In fact, we just issued a new FDA trade just moments ago. And from what we’re reading, it should take off nicely.
Here’s what we’re currently looking at.
On January 20, Columia Laboratories (CBRX) goes before an FDA panel to review Prochieve for the reduction of risk of preterm birth. Then, on February 26, CBRX will face FDA decision on Prochieve.
On January 28, Bristol Myers Squibb (BMY) faces an FDA decision on Dapagliflozin as a proposed treatment of adults with type 2 diabetes mellitus.
On January 28, Amylin Pharmaceuticals Inc (AMLN) faces FDA decision on Bydureon as proposed treatment for type 2 diabetes.
On February 9, Cell Therapeutics Inc. (CTIC) faces panel review of Pixuvri for treatment of relapsed or refractory Non-Hodgkin’s Lymphoma.
On February 14, Biosante Pharmaceuticals (BPAX) faces FDA decision on Bio-T-Gel for the treatment of male hypogonadism or low testosterone levels.
On March 8, Curis (CRIX) will face FDA decision on Vismodegib for treatment of advanced Basal Cell Carcinoma.
On March 28, Chelsea Therapeutics (CHTP) faces FDA decision on Northera for the treatment of symptomatic neurogenic orthostatic hypotension.
And on March 28, Bristol-Myers Squibb (BMY) faces FDA decision on ELIQUIS for prevention of stroke and systemic embolism in patients with atrial fibrillation.
